Jemincare initiates phase I clinical trial of anti-SARS-CoV-2 neutralizing antibody JMB2002

PR Newswire
January 20, 2021 — 13:53 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: China chinese pharmaceutical QQ Shanghai

Related News:

VYNDAMAX® (tafamidis) PBS-listed for adult patients with wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) with New York Heart Association (NYHA) Class I-II heart failure

May 4, 2024 — 18:00

Chinese president’s upcoming visit to bring new hope to Serbia’s development: Vucic

May 1, 2024 — 11:51

LYB to build integrated plastic waste recycling hub in Knapsack

April 29, 2024 — 19:00

Galaxy Macau, The World Class Integrated Resort, Unveils the "Experience Macao Singapore Roadshow"

April 27, 2024 — 15:06

HKU holds Entrance Scholarships Award Ceremony for 2023-24

April 26, 2024 — 17:05

GT20029 China Phase II Trial For AGA Reached Primary Endpoint

April 22, 2024 — 09:53

Inaugural ‘Korea Medical Innovation Research Forum’ regular seminar, a success

April 19, 2024 — 21:00

Students from JA Greece Win 2024 De La Vega Global Entrepreneurship Award

April 17, 2024 — 03:00

Pioneering Cutting-Edge Technologies: High-End Medical Imaging Developer VITAL HealthCare Debuts at CMEF

April 13, 2024 — 20:00